Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Aug 10;11(1):90.
doi: 10.1038/s41540-025-00572-4.

Generalized linear modeling of flow cytometry data to analyze immune responses in tuberculosis vaccine research

Affiliations

Generalized linear modeling of flow cytometry data to analyze immune responses in tuberculosis vaccine research

Pablo Maldonado et al. NPJ Syst Biol Appl. .

Abstract

Tuberculosis (TB) caused by Mycobacterium tuberculosis (Mtb) kills ~1.3 million people annually. Accordingly, vaccines and sophisticated analytical tools are necessary to evaluate their effectiveness. To address these challenges, we created a Generalized Linear Model (GLM) framework to evaluate high-dimensional flow cytometry data and the multivariable influences on immune responses, accommodating proportional and non-normal data, and violations of assumptions set by classical statistical evaluations. In naïve mice vaccinated with BCG boosted with ID93-GLA-SE, we used GLMs to assess the impact of sex, vaccination, and days post-infection on probabilities of immune cell phenotypes following Mtb challenge. We demonstrate enhanced T cell responses in the lung following BCG + ID93-GLA-SE compared to BCG or ID93-GLA-SE alone, with notable sex differences in humoral immunity. This framework highlights GLMs in assessing complex datasets while enhancing our comprehension of independent continuous and categorical variables on vaccine efficacy, and serves as a foundation for deeper, more complex scenarios.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Distribution and observed proportions of immune populations in vaccinated female and male C57Bl/6 mice infected with Mtb.
Mice were vaccinated with either Saline (control), BCG, ID93-GLA-SE, or BCG+ID93-GLA-SE and infected with Mtb. Lungs were processed for flow cytometry 14-, 56-, and 90-days post infection, and stained for A, B CD4+ CD44+, C, D CD8+, and E, F CD19+. A, C, E Distributions immune cell “success” in mice within each vaccination group. B, D, F Observed proportions of immune populations normalized to live leukocytes.
Fig. 2
Fig. 2. Estimated coefficients and odds ratios for immune responses in the infected mouse lung.
A, C, E Estimated coefficients on the outcome of immune responses for CD4+ CD44+, CD8+, and CD19+ cells for each one-, two-, and three-way interactions of group, day and sex derived from GLM logistical model output. B, D, F Odds ratios for exponentiated estimated effects.
Fig. 3
Fig. 3. Probability of immune phenotypes in the lung during Mtb infection.
AC Predicted probabilities of immune cell responses in the lung considering combinations of vaccination groups, days post-infection, and sex. A CD4+ CD44+, B CD8+, and) CD19+. All values were derived from the inverse of the logit function in our logistic regression model in R.
Fig. 4
Fig. 4. GLM framework workflow.
Our computational framework is comprised of four sequential data analysis steps which include, (1) Data acquisition from high dimensional flow cytometry and analysis software. (2) Initial data processing and exploration/visualization. (3) Logistical modeling withing the GLM framework. (4) Visualization of computed probabilities of outcomes based on variable interactions.

Similar articles

References

    1. Geneva: World Health Organization. Global Tuberculosis Report 2023. (ed World Health Organization). https://iris.who.int/ (World Health Organization, 2023).
    1. Choi, Y. H. et al. Safety and immunogenicity of the ID93 + GLA-SE tuberculosis vaccine in BCG-vaccinated healthy adults: a randomized, double-blind, placebo-controlled phase 2 trial. Infect. Dis. Ther.12, 1605–1624 (2023). - PMC - PubMed
    1. Kwon, K. W. et al. Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model. Sci. Rep.9, 15560 (2019). - PMC - PubMed
    1. Sagawa, Z. K. et al. Safety and immunogenicity of a thermo-stable ID93 + GLA-SE tuberculosis vaccine candidate in healthy adults. Nat. Commun.14, 1138 (2023). - PMC - PubMed
    1. Fatima, S., Kumari, A., Das, G. & Dwivedi, V. P. Tuberculosis vaccine: a journey from BCG to present. Life Sci.252, 117594 (2020). - PubMed

LinkOut - more resources